title: Clinicopathologic study on cholangiolocellular carcinoma.
abstract: We clinicopathologically studied 6 resected cases of cholangiolocarcinoma (CLC) including 2 referred cases from other hospitals. The frequency of CLC was 0.56% of the 708 consecutively resected cases of primary liver cancer and the mean age of CLC cases was 66 years. Three of the 6 cases (50%) were hepatitis C virus antibody (HCVab) positive, one (17%) was hepatitis B virus surface antigen (HBsAg) positive, and 2 (33%) were negative to both HCVAb and HBsAg. Serum levels of alpha-fetoprotein were slightly elavated only in 1 case. Clinically, 4 cases were diagnosed as hepatocellular carcinoma (HCC) and 2 cases as cholangiocellular carcinoma (CCC). Grossly, CLCs were whitish in color and solid, not encapsulated, and resembled CCC. Histologically, the tumor cells had eosinophilic cytoplasm with ovoid nuclei, and mild atypia. The tumor proliferated in an anastomosing pattern of Hering's canal-like small glands with an abundant fibrous stroma. Four of the 6 tumors (83%) consisted of only CLC and other 2 tumors contained CCC-like area and HCC-like area in a part of the nodules, respectively. Immunohistochemically, all tumors were positive to cytokeratin (CK) 7. CK8 were also positive in all of 6 cases. These results revealed that CLC had the clinical features resembling HCC but the morphologic features resembling CCC. It is suggested that CLC cells might be derived from Hering's canal or stem cells which have the intermediate features between hepatocytes and bile duct epithelium.
authors.affiliation: Department of Pathology, Kurume University School of Medicine, Kurume 830-0011, Japan. koji@med.kurume-u.ac.jp
authors.forename: K
authors.initials: K
authors.lastname: Shiota
authors.forename: J
authors.initials: J
authors.lastname: Taguchi
authors.forename: O
authors.initials: O
authors.lastname: Nakashima
authors.forename: M
authors.initials: M
authors.lastname: Nakashima
authors.forename: M
authors.initials: M
authors.lastname: Kojiro
mesh_terms: D000368:Aged; D001650:Bile Duct Neoplasms / Q000473:pathology* / Q000556:secondary / Q000601:surgery / Q000821:virology; D001653:Bile Ducts, Intrahepatic; D018395:CA-19-9 Antigen / Q000097:blood; D002272:Carcinoembryonic Antigen / Q000097:blood; D002467:Cell Nucleus / Q000473:pathology; D018281:Cholangiocarcinoma / Q000473:pathology* / Q000556:secondary / Q000601:surgery / Q000821:virology; D005260:Female; D006514:Hepatitis B Surface Antigens / Q000032:analysis; D018937:Hepatitis C Antibodies / Q000032:analysis; D006801:Humans; D008113:Liver Neoplasms / Q000473:pathology* / Q000601:surgery / Q000821:virology; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D000509:alpha-Fetoproteins / Q000032:analysis
chemical_list: D018395:CA-19-9 Antigen; D002272:Carcinoembryonic Antigen; D006514:Hepatitis B Surface Antigens; D018937:Hepatitis C Antibodies; D000509:alpha-Fetoproteins